Chemical Biology and Drug Design

JANUARY 5, 2025

5(4-Hydroxyphenyl)-2-(N-Phenyl amino)-1,3,4-Oxadiazole (Hppo) can considered as a versatile agent in designing novel pharmaceuticals. ABSTRACT Oxadiazole compounds are of great interest because they have a range of biological activities ranging from antioxidants to anticancer agents. Against this background, we wanted to demonstrate the antioxidant, enzyme inhibitory, and anticancer effects of 5(4-hydroxyphenyl)-2-(N-phenylamino)-1,3,4-oxadiazole (Hppo).

Bioinformatics 100

Bioinformatics Pharmaceuticals Drugs Research 100

FDA Law Blog: Biosimilars

JANUARY 5, 2025

By Deborah L. Livornese As promised in the Fall Unified Regulatory Agenda, FDA issued the final rule to establish the pathway to obtain marketing approval of a nonprescription drug product with an additional condition for nonprescription use (ACNU) on December 26, 2024, before the end of the calendar year. 89 Fed. Reg. 105288 (Dec. 26, 2024). We described the 2022 proposed rule and the ten-plus year history leading up to its issuance in our blog post here.

FDA 59

FDA Production Marketing Drugs 59

Perficient: Drug Development

JANUARY 5, 2025

Big news, Trailblazers! If youve ever worked with Lightning Web Components (LWC) , youve likely used the good old if:true and if:false directives for conditional rendering. These directives have served us well, but Salesforce has introduced a much-needed upgrade! Say hello to the modern conditional rendering directives : lwc:if, lwc:elseif, and lwc:else.

52

52

Chemical Biology and Drug Design

JANUARY 5, 2025

Dex decreased SOX9 expression and then reduced the transcriptional activation of DMT1, ameliorating ferroptosis to improve cerebral ischemia/reperfusion injury. ABSTRACT Cerebral ischemia/reperfusion injury (IRI) is pathologically associated with ferroptosis. Dexmedetomidine (Dex) exerts neuroprotective activity after cerebral IRI. Our work focused on probing the pharmacologic effect of Dex on ferroptosis during cerebral IRI and the mechanisms involved.

Regulations 100

Regulations Trials Research 100

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Perficient: Drug Development

JANUARY 5, 2025

Imagine this: youre on a treasure hunt. The treasure is hidden in a locked vault, and to open it, you need the right key. In Salesforce, when you need to access external systems, the key is what we call External Credentials and Named Credentials. But what exactly are they? Lets dive into this journey together and unravel their secrets in a simple and beginner-friendly way.

52

52